| EC Tree |
| 2. Transferases |
| 2.7 Transferring phosphorus-containing groups |
| 2.7.1 Phosphotransferases with an alcohol group as acceptor |
| ID: | 2.7.1.74 |
|---|---|
| Description: | Deoxycytidine kinase. |
| Cath: | 3.40.50.300; |
Click one PDB to see exact 3D structure provided by NGL.
Note: Use your mouse to drag, rotate, and zoom in and out of the structure. Mouse-over to identify atoms and bonds. Mouse controls documentation.| UniProtKB Enzyme Link: | UniProtKB 2.7.1.74 |
| BRENDA Enzyme Link: | BRENDA 2.7.1.74 |
| KEGG Enzyme Link: | KEGG2.7.1.74 |
| BioCyc Enzyme Link: | BioCyc 2.7.1.74 |
| ExPASy Enzyme Link: | ExPASy2.7.1.74 |
| EC2PDB Enzyme Link: | EC2PDB 2.7.1.74 |
| ExplorEnz Enzyme Link: | ExplorEnz 2.7.1.74 |
| PRIAM enzyme-specific profiles Link: | PRIAM 2.7.1.74 |
| IntEnz Enzyme Link: | IntEnz 2.7.1.74 |
| MEDLINE Enzyme Link: | MEDLINE 2.7.1.74 |
| RHEA:46040 | 2'-deoxycytidine + ATP = ADP + dCMP + H(+) |
| RULE(radius=1) | [*:1]-[OH;+0:2].[*:3]=[P;H0;+0:4](-[*:5])(-[*:6])-[O;H0;+0:7]-[*:8]>>[*:8]-[OH;+0:7].[*:3]=[P;H0;+0:4](-[*:5])(-[*:6])-[O;H0;+0:2]-[*:1] |
| Reaction | ![]() |
| Core-to-Core | No scaffolds atoms were exchanged as a result of the reaction |
| Title | Authors | Date | PubMed ID |
|---|---|---|---|
| Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues . | Hazra S, Ort S, Konrad M, Lavie A | 2010 Aug 10 | 20614893 |
| Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. | Hazra S, Sabini E, Ort S, Konrad M, Lavie A | 2009 Feb 17 | 19159229 |
| Structural basis for substrate promiscuity of dCK. | Sabini E, Hazra S, Ort S, Konrad M, Lavie A | 2008 May 2 | 18377927 |
| Structural basis for the preference of UTP over ATP in human deoxycytidine kinase: illuminating the role of main-chain reorganization. | Godsey MH, Ort S, Sabini E, Konrad M, Lavie A | 2006 Jan 17 | 16401075 |
| RHEA:46036 | 2'-deoxycytidine + UTP = dCMP + H(+) + UDP |
| RULE(radius=1) | [*:1]-[O;H0;+0:2]-[P;H0;+0:3](=[*:4])(-[*:5])-[*:6].[*:7]-[OH;+0:8]>>[*:1]-[OH;+0:2].[*:4]=[P;H0;+0:3](-[*:5])(-[*:6])-[O;H0;+0:8]-[*:7] |
| Reaction | ![]() |
| Core-to-Core | No scaffolds atoms were exchanged as a result of the reaction |
| Title | Authors | Date | PubMed ID |
|---|---|---|---|
| Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues . | Hazra S, Ort S, Konrad M, Lavie A | 2010 Aug 10 | 20614893 |
| Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. | Hazra S, Sabini E, Ort S, Konrad M, Lavie A | 2009 Feb 17 | 19159229 |
| Structural basis for substrate promiscuity of dCK. | Sabini E, Hazra S, Ort S, Konrad M, Lavie A | 2008 May 2 | 18377927 |
| Structural basis for the preference of UTP over ATP in human deoxycytidine kinase: illuminating the role of main-chain reorganization. | Godsey MH, Ort S, Sabini E, Konrad M, Lavie A | 2006 Jan 17 | 16401075 |
| RHEA:20061 | 2'-deoxycytidine + a ribonucleoside 5'-triphosphate = a ribonucleoside 5'-diphosphate + dCMP + H(+) |
| RULE(radius=1) | [*:1]-[O;H0;+0:2]-[P;H0;+0:3](=[*:4])(-[*:5])-[*:6].[*:7]-[OH;+0:8]>>[*:1]-[OH;+0:2].[*:4]=[P;H0;+0:3](-[*:5])(-[*:6])-[O;H0;+0:8]-[*:7] |
| Reaction | ![]() |
| Core-to-Core | No scaffolds atoms were exchanged as a result of the reaction |
| Title | Authors | Date | PubMed ID |
|---|---|---|---|
| Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues . | Hazra S, Ort S, Konrad M, Lavie A | 2010 Aug 10 | 20614893 |
| Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. | Hazra S, Sabini E, Ort S, Konrad M, Lavie A | 2009 Feb 17 | 19159229 |
| Structural basis for substrate promiscuity of dCK. | Sabini E, Hazra S, Ort S, Konrad M, Lavie A | 2008 May 2 | 18377927 |
| Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. | Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A | 2003 Jul | 12808445 |